Rocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 4.8% - Should You Sell?
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 4.8% - Here's Why...
MarketBeat·6d ago
More News
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Up 5.4% - What's Next?
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Up 5.4% - Time to Buy...
MarketBeat·8d ago
Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to Sell at Wall Street Zen
Wall Street Zen downgraded Rocket Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Sunday...
MarketBeat·9d ago
The Goldman Sachs Group Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock
The Goldman Sachs Group lifted their price target on shares of Rocket Pharmaceuticals from $2.00 to $3.00 and gave the stock a "sell" rating in a research note on Monday...
MarketBeat·15d ago
Brokers Set Expectations for RCKT FY2026 Earnings
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Analysts at Lifesci Capital issued their FY2026 earnings estimates for shares of Rocket Pharmaceuticals in a report released on Thursday...
MarketBeat·15d ago
Lifesci Capital Upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) to Strong-Buy
Lifesci Capital upgraded Rocket Pharmaceuticals to a "strong-buy" rating in a research report on Thursday...
MarketBeat·17d ago
Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen upgraded shares of Rocket Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·17d ago
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
Rocket Pharmaceuticals reports narrower-than-estimated Q4 loss. The company provides key updates on its pipeline candidates. Stock rises in after-hours trading.
Zacks·18d ago
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Up 14.3% Following Earnings Beat
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Up 14.3% Following Earnings Beat...
MarketBeat·18d ago
Cantor Fitzgerald Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock
Cantor Fitzgerald upped their price objective on shares of Rocket Pharmaceuticals from $8.00 to $10.00 and gave the stock an "overweight" rating in a report on Friday...